Tracy Bridges, MD
Allergy & Immunology · Albany, GANPI 1386749117
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $319,858 of the $364,257 with a category attached, or 87.8%. AstraZeneca accounts for 70.6% of it on its own, with 33 other manufacturers making up the rest. Among allergy & immunology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 892 payments — averaging $408.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$257K
- Regeneron Healthcare Solutions, Inc.$36K
- Amgen$26K
- Sanofi$12K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Boehringer Ingelheim$8K
- plus $18K from 28 others
Across 232 payments — averaging $5022.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma AS$268K
- Grifols Therapeutics LLC$248K
- AbbVie$179K
- AstraZeneca$128K
- Pfizer$104K
- Eli Lilly$90K
- plus $148K from 11 others
What the payments were for
- Consulting fees$6,7372%
- Speaking & faculty fees$319,85888%
- Travel & lodging$17,7815%
- Food & beverage$19,7785%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 284 | $257,126 |
| Regeneron Healthcare Solutions, Inc. | 88 | $36,140 |
| Amgen(2 entities) | 48 | $26,305 |
| Sanofi | 23 | $11,694 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $7,960 |
| Boehringer Ingelheim | 20 | $7,513 |
| Shire North American Group Inc | 16 | $4,700 |
| Grifols USA, LLC | 28 | $2,735 |
| Teva Pharmaceuticals USA, Inc. | 21 | $1,872 |
| GSK | 113 | $1,769 |
| Genentech USA, Inc. | 5 | $1,579 |
| Octapharma USA, Inc. | 13 | $862 |
| Biocryst US Sales Co., LLC | 29 | $722 |
| Pfizer | 47 | $710 |
| CSL Behring | 23 | $541 |
| Novartis | 22 | $431 |
| LEO Pharma Inc. | 12 | $271 |
| AbbVie | 12 | $268 |
| Kaleo, Inc. | 10 | $191 |
| Blueprint Medicines Corporation | 3 | $178 |
| ADMA Biomanufacturing LLC | 5 | $120 |
| Optinose US, Inc. | 4 | $76 |
| Pharming Healthcare, Inc. | 4 | $69 |
| Alk-abello, Inc | 4 | $68 |
| Incyte Corporation | 3 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $47 |
| Dermavant Sciences, Inc. | 2 | $43 |
| Bio Products Laboratory USA, Inc. | 2 | $43 |
| Cycle Pharmaceuticals Inc | 1 | $30 |
| Ionis Pharmaceuticals, Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$146,504
- AIRSUPRA$95,268
- DUPIXENT$45,572
- FASENRA$17,208
- CUVITRU$5,007
- Xembify$2,205
- AirDuo RespiClick$1,680
- ProAir Digihaler$1,680
- ArmonAir Digihaler$1,680
- HYQVIA$1,526
- XOLAIR$1,500
- BEVESPI AEROSPHERE$172
- AYVAKIT$135
- CUTAQUIG$124
How this compares
$364,257 in reported general payments places this provider in the 95th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 26 | $839,912 |
| Dupixent SyringeDupilumab | 99 | $389,003 |
| TezspireTezepelumab-Ekko | 54 | $234,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 218 | $172,054 |
| XolairOmalizumab | 50 | $165,528 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 31 | $161,904 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $125,699 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $56,759 |
| Dupixent PenDupilumab | 14 | $49,107 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 11 | $45,204 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $43,196 |
| Arnuity ElliptaFluticasone Furoate | 134 | $36,316 |
| SymbicortBudesonide/Formoterol Fumarate | 98 | $31,348 |
| Spiriva RespimatTiotropium Bromide | 23 | $19,655 |
| Azelastine Hcl | 549 | $17,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda, Hizentra | $541 | $1,001,81657 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $257,126 | $322,552231 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,769 | $264,277488 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $7,960 | $125,69912 claims |
| Boehringer IngelheimSpiriva Respimat | $7,513 | $19,65523 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $1,872 | $9,35923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Albany
- Erin CanningtonAlbany$13K
- Dennis RobinsonAlbany$12K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Lily HwangRoswell$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.